JP2019031502A5 - - Google Patents

Download PDF

Info

Publication number
JP2019031502A5
JP2019031502A5 JP2018177184A JP2018177184A JP2019031502A5 JP 2019031502 A5 JP2019031502 A5 JP 2019031502A5 JP 2018177184 A JP2018177184 A JP 2018177184A JP 2018177184 A JP2018177184 A JP 2018177184A JP 2019031502 A5 JP2019031502 A5 JP 2019031502A5
Authority
JP
Japan
Prior art keywords
depression
azabicyclo
dichlorophenyl
enantiomer
hexane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018177184A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019031502A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019031502A publication Critical patent/JP2019031502A/ja
Publication of JP2019031502A5 publication Critical patent/JP2019031502A5/ja
Pending legal-status Critical Current

Links

JP2018177184A 2010-12-03 2018-09-21 モノアミン神経伝達物質によって影響を受ける病態の処置における(+)−1−(3,4−ジクロロフェニル)−3−アザビシクロ[3.1.0]ヘキサンの調製および使用 Pending JP2019031502A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41976910P 2010-12-03 2010-12-03
US61/419,769 2010-12-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017000485A Division JP2017114861A (ja) 2010-12-03 2017-01-05 モノアミン神経伝達物質によって影響を受ける病態の処置における(+)−1−(3,4−ジクロロフェニル)−3−アザビシクロ[3.1.0]ヘキサンの調製および使用

Publications (2)

Publication Number Publication Date
JP2019031502A JP2019031502A (ja) 2019-02-28
JP2019031502A5 true JP2019031502A5 (cg-RX-API-DMAC7.html) 2019-06-13

Family

ID=46172308

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013542235A Pending JP2013544850A (ja) 2010-12-03 2011-12-02 モノアミン神経伝達物質によって影響を受ける病態の処置における(+)−1−(3,4−ジクロロフェニル)−3−アザビシクロ[3.1.0]ヘキサンの調製および使用
JP2017000485A Pending JP2017114861A (ja) 2010-12-03 2017-01-05 モノアミン神経伝達物質によって影響を受ける病態の処置における(+)−1−(3,4−ジクロロフェニル)−3−アザビシクロ[3.1.0]ヘキサンの調製および使用
JP2018177184A Pending JP2019031502A (ja) 2010-12-03 2018-09-21 モノアミン神経伝達物質によって影響を受ける病態の処置における(+)−1−(3,4−ジクロロフェニル)−3−アザビシクロ[3.1.0]ヘキサンの調製および使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2013542235A Pending JP2013544850A (ja) 2010-12-03 2011-12-02 モノアミン神経伝達物質によって影響を受ける病態の処置における(+)−1−(3,4−ジクロロフェニル)−3−アザビシクロ[3.1.0]ヘキサンの調製および使用
JP2017000485A Pending JP2017114861A (ja) 2010-12-03 2017-01-05 モノアミン神経伝達物質によって影響を受ける病態の処置における(+)−1−(3,4−ジクロロフェニル)−3−アザビシクロ[3.1.0]ヘキサンの調製および使用

Country Status (8)

Country Link
US (5) US20120258994A1 (cg-RX-API-DMAC7.html)
EP (1) EP2646019A4 (cg-RX-API-DMAC7.html)
JP (3) JP2013544850A (cg-RX-API-DMAC7.html)
KR (1) KR20140053822A (cg-RX-API-DMAC7.html)
AU (1) AU2011336318A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013013572A2 (cg-RX-API-DMAC7.html)
CA (1) CA2834713A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012075473A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010521496A (ja) 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク. キラル精製置換ベンゾチアゾールジアミンの合成
CA2734491A1 (en) 2008-08-19 2010-02-25 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
US20140228421A1 (en) * 2011-09-07 2014-08-14 Anthony McKinney Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters
US20130123238A1 (en) * 2011-11-16 2013-05-16 Anthony Alexander McKINNEY Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane to treat addictive and alcohol-related disorders
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
WO2014113844A1 (en) * 2013-01-28 2014-07-31 Brc Operations Pty Limited White matter diffusion tensor imaging test to predict treatment outcomes in medical treatment
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
WO2014134569A1 (en) * 2013-02-28 2014-09-04 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
JP2016518406A (ja) * 2013-05-07 2016-06-23 ユーシミクス・バイオサイエンス・インコーポレイテッドEuthymics Bioscience,Inc. 嗜癖障害およびアルコール関連障害を治療するための(+)−1−(3,4−ジクロロフェニル)−3−アザビシクロ[3.1.0]へキサンの使用
US9566264B2 (en) 2013-07-01 2017-02-14 Euthymics Bioscience, Inc. Combinations and methods
WO2015006708A1 (en) 2013-07-12 2015-01-15 Knopp Biosciences Llc Treating elevated levels of eosinophils and/or basophils
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
ES2871556T3 (es) 2013-08-13 2021-10-29 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de la urticaria crónica
EP3038467B1 (en) 2013-08-13 2020-07-29 Knopp Biosciences LLC Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
CA2930410A1 (en) * 2013-11-11 2015-05-14 Impax Laboratories, Inc. Rapidly disintegrating formulations and methods of use
CN104683094B (zh) * 2013-11-29 2018-10-26 上海华虹集成电路有限责任公司 用于rsa密码的蒙哥马利阶梯算法
US20160303077A1 (en) * 2013-12-09 2016-10-20 Neurovance, Inc. Novel compositions
PT3474844T (pt) 2016-06-28 2022-11-08 Trichomeshell Ltd Uma forma de dosagem para ser vaporizada e fumada
JP7125791B2 (ja) * 2018-05-23 2022-08-25 シャンハイ ダブリュディー ファーマシューティカル カンパニー,リミティド 活性薬物成分の放出制御システムおよびその製造方法
US11911513B2 (en) 2018-05-23 2024-02-27 Shanghai Wd Pharmaceutical Co., Ltd Controlled-release system of active pharmaceutical ingredient and preparation method therefor
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
WO2020142545A1 (en) 2018-12-31 2020-07-09 Ethismos Research, Inc. Novel methods
US11554154B2 (en) * 2020-07-22 2023-01-17 Biolite, Inc. Polygala extract for the treatment of major depressive disorder
JP2024532625A (ja) * 2021-08-31 2024-09-05 エシスモス リサーチ, インコーポレイテッド 疼痛および関連症状を予防および治療する方法
CN116813547A (zh) * 2023-06-29 2023-09-29 爱斯特(成都)生物制药股份有限公司 一种制备3-氮杂双环[3,2,1]辛烷盐酸盐的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL65843A (en) * 1977-08-11 1986-12-31 American Cyanamid Co Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type
US6372919B1 (en) * 2001-01-11 2002-04-16 Dov Pharmaceutical, Inc. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent
US20070043100A1 (en) * 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
KR20070054208A (ko) * 2004-08-18 2007-05-28 도브 파마슈티칼 인코포레이티드 아자비사이클로헥산의 신규한 다형체
TW200735878A (en) * 2005-11-18 2007-10-01 Astrazeneca Ab Pharmaceutical compositions
US20140228421A1 (en) * 2011-09-07 2014-08-14 Anthony McKinney Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters
US20130123238A1 (en) * 2011-11-16 2013-05-16 Anthony Alexander McKINNEY Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane to treat addictive and alcohol-related disorders

Similar Documents

Publication Publication Date Title
JP2019031502A5 (cg-RX-API-DMAC7.html)
JP2023076465A (ja) デクスメデトミジン製剤を使用する睡眠障害の予防または治療
JP2019059760A5 (cg-RX-API-DMAC7.html)
JP2008534627A5 (cg-RX-API-DMAC7.html)
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
JP2010535252A5 (cg-RX-API-DMAC7.html)
JP2007530622A5 (cg-RX-API-DMAC7.html)
JP2013544850A5 (cg-RX-API-DMAC7.html)
JP2014505688A5 (cg-RX-API-DMAC7.html)
RU2008150622A (ru) Лечение агонистом мелатонина
CN110114083A (zh) 一种预防和治疗脂肪肝的方法
JP2020534270A5 (cg-RX-API-DMAC7.html)
JP2003504303A5 (cg-RX-API-DMAC7.html)
JP2018521007A5 (cg-RX-API-DMAC7.html)
JP2005508872A5 (cg-RX-API-DMAC7.html)
JP2016501219A5 (cg-RX-API-DMAC7.html)
JP2020529995A5 (cg-RX-API-DMAC7.html)
JP2013536837A5 (cg-RX-API-DMAC7.html)
WO2009003694A3 (en) Method for treating diseases related to mitochondrial dysfunction
CN101801361A (zh) 抑郁症的治疗
JP2014534229A5 (cg-RX-API-DMAC7.html)
RU2006143659A (ru) Применение ребоксетина для лечения боли
JP2011508727A5 (cg-RX-API-DMAC7.html)
WO2002066468A3 (en) Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands
RU2007102290A (ru) Способ лечения нарушений и заболеваний нервной системы